Combination therapies with specific CCND1/CDK4 and CCND1/CDK2 inhibitors and p53-activators targeted to luminal breast cancer sub-types associated with elevated CCND1 expression should be the most beneficial. Here, CDK2 is linked to breast carcinoma.